by Raynovich Rod | Jul 25, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Diagnostics and Tools Stocks Are At New Highs We will be attending the American Association of Clinical Chemistry Meeting in Houston next week. Our focus stocks are summarized below and as you can see they have already made huge moves this year.In the past we have...
by Raynovich Rod | Jul 24, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Movers in Rayno Diagnostics and Tools Stocks On a lackluster day in the market two of our picks were up big,two others exceeded one year highs. Illumina (ILMN $81) was up 10% on earnings to an all time high recovering from its downdraft in 2011. Revenues were up 23%...
by Raynovich Rod | Jul 11, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Strong NASDAQ Up 1.35%-IBB Hits 188.82 All Time High A stealth rally that began with futures after the close yesterday was triggered by Bernanke comments interpreted by the market as backtracking on “tapering”. Maybe Bernanke was trying to soften his...
by Raynovich Rod | Jul 8, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Are Mixed-Biopharma Weak But Diagnostics Strong The life science sector traded along with NASDAQ today so as the NAZ sold off (tech stock weakness) biotech followed. The IBB (181.51) off 0.58% could not regain momentum as of mid-day trading after a...
by Raynovich Rod | Jul 2, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Biotechnology Sector (IBB 178) Up Over 30% YTD Many Rayno Focus Stocks Outperformed the Market NASDAQ 3431 , S&P 1615 Biopharmaceutical-Top 5 Stocks- % Up YTD Albany Molecular (AMRI) 140.7 Alkermes (ALKS) 59.3 Astex (ASTX) up 49.5 Biogen Idec (BIIB) up 48.9...
by Raynovich Rod | Jun 27, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Bond Market Stabilizes A strong bond auction today for the 7 Year Treasury at an interest rate of 1.94% helped support the three day rally easing investor concerns about rising interest rates and liquidation of bonds. European and Japanese stocks were also up. Bond...
by Raynovich Rod | Jun 25, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Global Economic Picture Not Good-Healthcare A Laggard on Rally Day Strong housing and durable goods data supported the rally today taking the S&P up 0.95% and NASDAQ up 0.82%. Comments from the China’s Central Bank helped a recovery from a free fall in the...
by Raynovich Rod | Jun 20, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years...
by Raynovich Rod | Jun 13, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
6/14 Supreme Court Ruling on Genetic Tests Takes Down Myriad Stock (MYGN $30.50)-Off Another 3% but still up 13% YTD. The Supreme Court ruling opens up competition for Myriad’s breast cancer tests as well as other genetic disease markers.The immediate reaction...
by Raynovich Rod | Jun 11, 2013 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Holding Up Amidst Volatility-Stay Cautious Biotech stocks are mixed today as volatility from currency moves and violence in Turkey and the Middle East gives pause to investors. Bonds have corrected almost 5% prompting an exit from bond funds as the...